Cyclophosphamide
Low Grade Lymphoma
AmgenSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Low Grade Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bortezomib Amgen | Phase 1 | CC |
Vorinostat Amgen | Phase 1 | CC |
Irinotecan Amgen | Phase 1 | CC |
(+)-VINCRISTINE Amgen | Phase 1 | CC |
DEXAMETHASONE Amgen | Phase 1 | CC |
View all 9 →
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →